Global Migraine Drugs Market Forecast Report, 2018 to 2025
by Susan Hill Business ConsultantThe global migraine
drugs market size is expected to be valued at USD 7.8 billion by 2025, as per a
new report by Grand View Research, Inc., exhibiting an 18.0% CAGR during the
forecast period. The market is largely driven by factors such as rise in disease
prevalence, development of novel therapies, lifestyle changes, and hormonal
medications.
Migraine is a debilitating neurological disease
characterized by recurrent attacks of severe throbbing head pain that can
last for more than three days. Migraine pain may get worse on movement,
preventing the patient from carrying out normal, day-to-day activities. In
about one-third of attacks, both sides of the head, face, or neck are affected.
Over the past five years, the global migraine drugs
market has been relatively stagnant, with the market mainly dominated by usage
of generic triptans and other off-label drugs. Majority of the currently
prescribed drugs for both acute and preventative treatment are associated with
poor efficacy and an unfavorable side-effect profile.
Launch of Amgen/ Novartis’ CGRP mAb Aimovig and Teva
Pharma’s Ajovy is the first step toward revolutionizing the treatment paradigm
of migraine prevention. For drug manufacturers likely to enter the market by
2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be
a key differentiating factor as all CGRP-based therapies have a similar
efficacy and safety profile.
Further key findings from the report suggest:
- Germany leads the European market, driven by rising disease
prevalence, novel drug launches, and increase in R&D activities
- The acute migraine treatment market will be supported by rapid
uptake of novel drug classes such as CGRP receptor antagonists and ditans
currently under active investigation in multiple Phase II/III trials
- Biohaven’s rimegepant is expected to face competition from
Allergan's ubrogepant, which has shown superior efficacy in Phase III
trials compared to rimegepant
- Eli Lilly’s Phase III 5-HT1F receptor agonist Lasmiditan is expected
to be a novel first-line non triptan acute treatment option for patients
in whom triptans are contradicted
- Approximately 20% of patients seeking preventive treatment for
migraine do not respond to available generic medications. Several biologics and small
molecules drugs are undergoing active development to target high unmet
needs in the preventive treatment segment
- Drugs with novel targets in early-phase development include AOBiome
Therapeutics’ AOB-203 (antibacterial), Winston Pharma’s Dolorac (histamine
H1 receptor antagonists), NeuroAxons’ NXN-188 (combination of NOS
inhibitor and a triptan), and Biohaven’s BHV-3500 (gepant). These novel
agents are under evaluation for both episodic and chronic migraine in
multiple Phase I/II trials.
Grand View Research has segmented the global
migraine drugs market based on treatment, therapeutic class, route of
administration, and country:
Migraine
Drugs Treatment Outlook (Revenue, USD Million, 2017 - 2025)
- Acute / Abortive Treatment
- Preventive/ Prophylactic Treatment
Migraine
Drugs Therapeutic Class Outlook (Revenue, USD Million, 2017 - 2025)
- Triptans
- Acetylcholine Inhibitors
- Ergot Alkaloids
- NSAIDs
- Ditans
- CGRP small molecule antagonists
- CGRP monoclonal antibodies
- Others
Migraine
Drugs Route of Administration Outlook (Revenue, USD Million, 2017 - 2025)
- Oral
- Injectables
- Others
Migraine
Drugs Country Outlook (Revenue, USD Million, 2017 - 2025)
- U.S.
- U.K.
- France
- Germany
- Italy
- Spain
- Japan
Access full research report on global migraine drugs market:
https://www.grandviewresearch.com/industry-analysis/migraine-drugs-market
Sponsor Ads
Created on Jun 27th 2019 08:03. Viewed 319 times.